Moberg Pharma meets primary endpoint for MOB-015 in a Phase 3 study for the treatment of onychomycosis
STOCKHOLM, December 9[th], 2019, Moberg Pharma AB (OMX: MOB) announces that MOB-015 (topical terbinafine) met the primary endpoint as well as key secondary endpoints in the North American Phase 3 study including 365 patients with mild to moderate toenail onychomycosis (nail fungus). At week 52, significantly more patients reached complete cure for MOB-015 than for vehicle (p=0.019), following 48 weeks of daily treatment.The purpose of this randomized, multicenter, controlled clinical Phase 3 study was to evaluate the efficacy and safety of MOB-015 in patients with mild to moderate distal